Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: A meta-analysis

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Zhao, Fengzhi ^a   Xu, Meng ^a   Lei, Honcho ^a   Zhou, Ziqi ^a   Wang, Liang ^a   Li, Ping ^a   Zhao, Jianfu ^a   Hu, Penghui ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CELL PROTEIN; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER PATIENT; CANCER STAGING; CHINESE; CLINICAL FEATURE; DATA BASE; EGFR GENE; EML4 ALK FUSION GENE; ETHNICITY; FUSION GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW; FEMALE; GENETIC ASSOCIATION STUDY; GENETICS; MALE; META ANALYSIS; MUTATION; PATHOPHYSIOLOGY;

ECHINODERMATA;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84924362694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117333     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 1:69-90.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics. Cancer J Clin 56 106-130 PMID: 16514137
3. Ettinger DS, Bepler G, Bueno R, Chang JY, Chirieac LR, et al. (2006) Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:548-582. PMID: 16813724
4. Greene FL, Sobin LH (2002) The TNM system: our language for cancer care. J Surg Oncol 80:119-20. PMID: 12115792
5. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, et al. (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109. PMID: 15020612
6. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, et al. (2011) EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 71: 241-243. doi: 10.1016/j.lungcan.2010.11.014 PMID: 21168933
7. Giuseppe G (2002) Targeted therapy in non-small cell lung cancer. Lung Cancer 38: S29-S32. PMID: 12431826
8. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566. PMID: 17625570
9. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G, et al. (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23. PMID: 18097461
10. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, et al. (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 105:19893-19897. doi: 10.1073/pnas.0805381105 PMID: 19064915
11. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703. doi: 10.1056/NEJMoa1006448 PMID: 20979469
12. Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4: 1450-1454. doi: 10.1097/JTO.0b013e3181c4dedb PMID: 20009909
13. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377-384. PMID: 9764259
14. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, et al. (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3:13-17. doi: 10.1097/JTO.0b013e31815e8b60 PMID: 18166835
15. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566. PMID: 17625570
16. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, et al. (2008) EML4- ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61: 163-169. doi: 10.1016/j.lungcan.2007.12.013 PMID: 18242762
17. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14: 6618-6624. doi: 10.1158/1078-0432. CCR-08-1018 PMID: 18927303
18. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, et al. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12:1004-1012. doi: 10.1016/S1470-2045(11)70232-7 PMID: 21933749
19. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723-1733. doi: 10.1002/cncr.24181 PMID: 19170230
20. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22:508-515. doi: 10.1038/modpathol.2009.2 PMID: 19234440
21. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174:661-670. doi: 10.2353/ajpath.2009.080755 PMID: 19147828
22. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216-5223. doi: 10.1158/1078-0432.CCR-09-0802 PMID: 19671850
23. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, et al. (2010) Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63: 1066-1070. doi: 10.1136/jcp.2010.081166 PMID: 20935334
24. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, et al. (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17:889-897. doi: 10.1245/s10434-009-0808-7 PMID: 20183914
25. Zhang X, Zhang S, Yang X, Yand J, Zhou Q, et al. (2010) Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9:1-12. doi: 10.1186/1476-4598-9-1 PMID: 20051109
26. Sanders HR, Li HR, Bruey JM, Scheerle JA, Meloni-Ehrig AM, et al. (2011) Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 204: 45-52. doi: 10.1016/j.cancergencyto.2010.08.024 PMID: 21356191
27. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253. doi: 10.1200/JCO.2009.22.6993 PMID: 19667264
28. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, et al. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22:2616-2624. doi: 10.1093/annonc/mdr489 PMID: 22071650
29. Jin G, Jeon HS, Lee EB, Kang HR, Yoo SS, et al. (2012) EML4-ALK fusion gene in Korean non-small cell lung cancer. J Korean Med Sci 27:228-230. doi: 10.3346/jkms.2012.27.2.228 PMID: 22323876
30. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, et al. (2012) Distinct clinical features and outcomes in never-smokers with non-small cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 118:729-739. doi: 10.1002/cncr.26311 PMID: 21720997
31. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283. doi: 10.1158/1078-0432.CCR-08-0168 PMID: 18594010
32. Lin XM, Mo JM, Zou M, Zeng AP, Yu QT, et al. (2012) Detection of EML4-ALK fusion gene and analysis of its clinical features in NSCLC patients with EGFR mutation. Chinese Journal of Pathophysiology 28:1135-1139.
33. Han XH, Zhang NN, Ma L, Lin DM, Hao XZ, et al. (2013) Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch 463:583-591. doi: 10.1007/s00428-013-1472-7 PMID: 23955278
34. Takamochi K, Takeuchi K, Hayashi T, Oh S, Suzuki K (2013) A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: A comprehensive study of surgically treated Japanese patients. PLoS One 8:1-9.
35. Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, et al. (2013) Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, Immunohistochemistry, and Real-Time Quantitative RT-PCR on paraffin-embedded tissues. PLoS One 8:1-8.
36. Fang P, Feng GH, Lin L, Hu B, Wu H, et al. (2013) Expression of EML4-ALK and EGFR mutation in lung ademocarcinoma. J Med Res 42:109-112.
37. Zhong S, Zhang HP, Zheng J (2013) Detection of EMIA-ALK fusion gene in non-small cell lung cancer and its clinicopathologic correlation. Chin J Pathol 42:252-256.
38. Wang M, Yang JY, Li JC, Chen YX (2013) Expression of EML4-ALK in non-small cell lung cancer and its clinical significance. Chinese Clinical Oncology 18:688-690.
39. Li Y, Li YG, Yang T, Wei S, Wang J, et al. (2013) Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 8:1-12.
40. Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, et al. (2014) Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 20:1383-1392. doi: 10.1158/1078-0432.CCR-13-0699 PMID: 24443522
41. Nalbandian A, Yan BS, Pichugin A, Bronson RT, Kramnik I (2009) Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene 28:1928-1938. doi: 10.1038/onc.2009.32 PMID: 19330024
42. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283. doi: 10.1158/1078-0432.CCR-08-0168 PMID: 18594010
43. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733. doi: 10.1002/cncr.24181 PMID: 19170230
44. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, et al. (2012) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76: 403-409. doi: 10.1016/j.lungcan.2011.11.008 PMID: 22129856
45. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 15:415-453
46. Fallet V, Cadranel J, Doubre H, Toper C, Monnet I, et al. (2014) Prospective screening for ALK: Clinical features and outcome according to ALK status. Eur J Cancer 50:1239-1246. doi: 10.1016/j.ejca.2014.02.001 PMID: 24589437
47. Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, et al. (2013) Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 8:1-8.
48. Kuo YW, Wu SG, Ho CC, Shih JY (2010) Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 5: 2039-2040. doi: 10.1097/JTO.0b013e3181f43274 PMID: 21102267
49. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, et al. (2011) EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 71: 241-243. doi: 10.1016/j.lungcan.2010.11.014 PMID: 21168933